In addition, the effects of HMGB1 overexpression on PFS were consistent among different tumor types: hepatocellular carcinoma (HR: 1.63; 95% CI, 1.24-2.14), nasopharyngeal carcinoma (HR: 1.94; 95% CI, 1.10-3.43), head and neck squamous-cell carcinoma (HR: 2.12; 95% CI, 1.19-3.78), bladder cancer (HR: 5.27; 95% CI, 2.99-9.28), prostate cancer (HR: 2.35; 95% CI, 1.37-6.36), and cervical carcinoma (HR: 2.93; 95% CI, 1.45-6.33) (Figure 6). This evidence concerns the gene HMGB1 and urinary bladder carcinoma.